Bayforest Capital Ltd Boosts Stake in Medpace Holdings, Inc. $MEDP

Bayforest Capital Ltd raised its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 8,605.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,741 shares of the company’s stock after acquiring an additional 1,721 shares during the quarter. Medpace makes up about 0.4% of Bayforest Capital Ltd’s portfolio, making the stock its 28th biggest position. Bayforest Capital Ltd’s holdings in Medpace were worth $895,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in MEDP. Wasatch Advisors LP boosted its position in Medpace by 14.0% during the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after purchasing an additional 116,354 shares in the last quarter. Mawer Investment Management Ltd. boosted its holdings in shares of Medpace by 17.4% in the 2nd quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock valued at $256,559,000 after buying an additional 121,213 shares in the last quarter. AQR Capital Management LLC grew its position in shares of Medpace by 15.1% in the 2nd quarter. AQR Capital Management LLC now owns 621,184 shares of the company’s stock worth $193,269,000 after buying an additional 81,637 shares during the last quarter. TD Asset Management Inc raised its stake in shares of Medpace by 15.6% during the 2nd quarter. TD Asset Management Inc now owns 457,645 shares of the company’s stock worth $143,636,000 after acquiring an additional 61,764 shares in the last quarter. Finally, Epoch Investment Partners Inc. raised its stake in shares of Medpace by 11.4% during the 2nd quarter. Epoch Investment Partners Inc. now owns 445,231 shares of the company’s stock worth $139,740,000 after acquiring an additional 45,435 shares in the last quarter. 77.98% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have weighed in on MEDP. Cowen restated a “sell” rating on shares of Medpace in a research note on Friday, October 24th. Zacks Research raised Medpace from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 27th. TD Cowen boosted their target price on Medpace from $356.00 to $462.00 and gave the stock a “sell” rating in a research note on Friday, October 24th. Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, December 20th. Finally, Robert W. Baird set a $613.00 price target on Medpace in a report on Friday, October 24th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, ten have given a Hold rating and four have given a Sell rating to the company. Based on data from MarketBeat, Medpace currently has an average rating of “Hold” and an average target price of $491.27.

Medpace Price Performance

Shares of MEDP stock opened at $595.00 on Friday. The business has a fifty day moving average of $581.05 and a 200 day moving average of $500.93. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $626.26. The firm has a market capitalization of $16.76 billion, a price-to-earnings ratio of 41.61, a price-to-earnings-growth ratio of 2.00 and a beta of 1.43.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The business had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. During the same period in the prior year, the company earned $3.01 earnings per share. The company’s revenue was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, equities research analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Insider Buying and Selling

In other news, VP Susan E. Burwig sold 20,000 shares of the company’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $609.15, for a total value of $12,183,000.00. Following the sale, the vice president directly owned 27,500 shares of the company’s stock, valued at $16,751,625. This represents a 42.11% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO August J. Troendle sold 59,025 shares of the stock in a transaction on Monday, November 24th. The stock was sold at an average price of $607.78, for a total transaction of $35,874,214.50. Following the completion of the sale, the chief executive officer owned 774,602 shares in the company, valued at $470,787,603.56. The trade was a 7.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 387,925 shares of company stock worth $233,386,647. 20.30% of the stock is owned by company insiders.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.